In conclusion, we have confirmed that PARP1 is essential for HR in ovarian cancer cell lines lacking BRCA2 and treatment with rucaparib, a PARP inhibitor, increases the formation of γ-H2AX foci. This evidence concerns the gene H2AX and ovarian carcinoma.